SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 6.6% Stake in Avanos Medical Inc.
Beneficial Ownership Report
T. Rowe Price Investment Management, Inc. has reported a 6.6% beneficial ownership stake in Avanos Medical Inc., as detailed in a recent Schedule 13G filing.
Summary
- T. Rowe Price Investment Management, Inc. filed an Amendment No. 1 to Schedule 13G concerning its beneficial ownership in AVANOS MEDICAL INC.
- As of December 31, 2024, T. Rowe Price Investment Management, Inc. beneficially owned 3,011,312 shares of AVANOS MEDICAL INC's common stock.
- This ownership represents 6.6% of the total outstanding common stock of AVANOS MEDICAL INC.
- The reporting entity holds sole voting power over 2,993,829 shares and sole dispositive power over 3,011,312 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter market sentiment towards the issuer.
Positives
- The disclosure of a significant 6.6% stake by a reputable institutional investor like T. Rowe Price Investment Management, Inc. may signal confidence in Avanos Medical Inc. from a major market participant.
Future Outlook
The document is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer or the reporting entity regarding the issuer's future performance.
Industry Context
This filing is a routine disclosure of an institutional investor's stake in a publicly traded company within the healthcare or medical device sector (AVANOS MEDICAL INC). It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings in the company, which can be a factor in assessing investor confidence and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership as of this date). |
| 02/14/2025 | Date of filing and signature of the Schedule 13G Amendment No. 1. |
Keywords
AVANOS MEDICAL INC, T. Rowe Price Investment Management, Schedule 13G, beneficial ownership, institutional investment, common stock, medical devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.